Scribe Therapeutics
biotech · gene editing · cardiovascular disease
Eli Lilly-backed Scribe Therapeutics jumps 67% in upsized $128.7M IPO debut
July 24, 2026
Investors are betting gene-editing therapies can tackle common diseases like high cholesterol, not just ultra-rare genetic disorders.
Read the Full Story in Velocity
Get curated startup and tech news with new stories published daily, company insights, and real-time alerts.